Premium
Epidemiology, clinical characteristics, and outcome of invasive aspergillosis in renal transplant patients
Author(s) -
Hoyo I.,
Sanclemente G.,
Bellacasa J. Puig,
Cofán F.,
Ricart M.J.,
Cardona M.,
Colmenero J.,
Fernández J.,
Escorsell A.,
Navasa M.,
Moreno A.,
Cervera C.
Publication year - 2014
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12301
Subject(s) - medicine , transplantation , aspergillosis , epidemiology , gastroenterology , cohort , liver transplantation , complication , kidney disease , kidney , surgery , immunology
Background Invasive aspergillosis ( IA ) has been considered an infrequent complication after renal transplantation. We aimed to evaluate the differences in clinical and epidemiologic characteristics of IA between renal and other types of transplantation. Methods We reviewed all cases of solid organ transplant ( SOT ) recipients from Hospital Clinic at Barcelona, who had proven and probable IA , according to the EORTC / MSG criteria, between June 2003 and December 2010. Results A total of 1762 transplants were performed. From this cohort, 27 cases of IA were diagnosed (1.5%): in 56% (15/27) liver, 33% (9/27) kidney, and 11% (3/27) combined transplant. The median onset time from renal and non‐renal transplants to IA was 217 and 10 days, respectively ( P < 0.001). There were 6 cases (22%) of late IA (>6 months), all in kidney recipients ( P < 0.001). Renal transplant patients with IA more frequently had chronic lung disease (44% vs. 6%) and chronic heart failure (33% vs. 6%); they also had none of the classical risk factors for IA defined for liver transplantation (0% vs. 33%, P = 0.001), and therefore they did not receive antifungal prophylaxis (0% vs. 72%, P = 0.001). In 14/24 patients, serum galactomannan antigen was positive, and this related to higher mortality. Conclusions While classical risk factors described for IA in liver recipients are still valid, IA appears later in renal patients and is commonly associated with co‐morbid conditions.